Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Gut 2006;55(Supplement 1):i16-i35; doi:10.1136/gut.2005.081950b
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v55,p437)
Right arrow Correction (v55,p592)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Travis, S P L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Travis, S P L
Related Collections
Right arrow Gastrointestinal Surgery
Right arrow Gastro-esophageal reflux
Right arrow Inflammatory bowel disease
Right arrow Guidelines
Right arrow Drugs: gastrointestinal system

European evidence based consensus on the diagnosis and management of Crohn’s disease: current management

S P L Travis1, E F Stange2, M Lémann3, T Öresland4, Y Chowers5, A Forbes6, G D’Haens7, G Kitis8, A Cortot9, C Prantera10, P Marteau11, J-F Colombel12, P Gionchetti13, Y Bouhnik14, E Tiret15, J Kroesen16, M Starlinger17, N J Mortensen18 for the European Crohn’s and Colitis Organisation (ECCO)

1 John Radcliffe Hospital, Oxford, UK
2 Chefarzt, Abteilung für Innere Medizin 1 Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie, Robert Bosch Krankenhaus, Stuttgart, Germany
3 Service de Gastroentérologie, Hôpital Saint-Louis, Paris, France
4 Colorectal Unit, Department of Surgery, Sahlgrenska Universiteitssjukhuset/Östra, Gothenburg, Sweden
5 Chaim Sheba Medical Center, Tel Hashomer, Israel 52621
6 University College Hospital, London, UK
7 Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
8 Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
9 Department of Gastroenterology, University Hospital, Lille, France
10 Azienda Ospedaliera S. Camillo-Forlanini, Unita Operativa di Gastroenterologia, Rome, Italy
11 Hospital Européen Department of Gastroenterology, Paris, France
12 Hospital Huriez, Department of HepatoGastroenterology, CH et U, Lille, France
13 Universita di Bologna, Bologna, Italy
14 Hospital Lariboisière, Department of Gastroenterology, Paris, France
15 Inserm, Paris, France, and Universite Pierre et Marie Curie, Paris, France
16 Chirurgische Klinik I (Allgemein-, Gefäß- und Thoraxchirurgie), Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany
17 Institute of Pathology, University of Graz, Austria
18 Department of Colorectal Surgery, John Radcliffe, Oxford, UK

Correspondence to:
Correspondence to:
Dr S P L Travis
John Radcliffe Hospital, Oxford OX3 9DU, UK; simon.travis{at}orh.nhs.uk; Professor E F Stange, Department of Internal Medicine 1, Robert Bosch Krankenhaus, PO Box 501120, Auerbachstr 110, 70341 Stuttgart, Germany; Eduard.Stange{at}rbk.de


ABSTRACT
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn’s disease. The third section on special situations in Crohn’s disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn’s disease.


Abbreviations: 5-ASA, mesalazine; AZA, azathioprine; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CRP, C reactive protein; CsA, cyclosporin; ECCO, European Crohn’s and Colitis Organisation; ESR, erythrocyte sedimentation rate; IBD, inflammatory bowel disease; IFX, infliximab; MTX, methotrexate; 6-MP, 6-mercaptopurine; NNH, number needed to harm; NNT, number needed to treat; UC, ulcerative colitis

Keywords: Crohn’s disease; treatment; mesalazine; corticosteroids; azathioprine; infliximab; surgery




This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
N. Fujita, T. Itoh, H. Omori, M. Fukuda, T. Noda, and T. Yoshimori
The Atg16L Complex Specifies the Site of LC3 Lipidation for Membrane Biogenesis in Autophagy
Mol. Biol. Cell, May 1, 2008; 19(5): 2092 - 2100.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. J. Shin and M. T. Collins
Thiopurine Drugs Azathioprine and 6-Mercaptopurine Inhibit Mycobacterium paratuberculosis Growth In Vitro
Antimicrob. Agents Chemother., February 1, 2008; 52(2): 418 - 426.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
A Cassinotti, C Annaloro, S Ardizzone, F Onida, A D. Volpe, M Clerici, P Usardi, S Greco, G Maconi, G B. Porro, et al.
Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease
Gut, February 1, 2008; 57(2): 211 - 217.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
A. Salar, X. Bessa, E. Muniz, D. Monfort, C. Besses, and M. Andreu
Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease
Gut, August 1, 2007; 56(8): 1169 - 1170.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology